Salvage tigecycline in high risk febrile neutropenic patients with hematological malignancies: a prospective multicenter study

References

• Chinese Society of Hematology Chinese Medical Association, Chinese Medical Doctor Association Hematology Branch. Chinese guidelines for the clinical application of antibacterial drugs for agranulocytosis with fever (2016). Chin J Hematol. 2016;37:353–359.
   Google Scholar
• Hu FP, Zhu DM, Wang F, et al. Report of CHINET antimicrobial resistance surveillance program in 2015. Chin J Infect Chemother. 2016;16:685–694.
   Google Scholar
• Deng Q, Li Q, Lin XM, et al. Epidemiology and antimicrobial resistance of clinical isolates about hospital infection from patients with hematological diseases. Chin J Hematol. 2012;33:994–999.
   Google Scholar
• Yan CH, Xu T, Zheng XY, et al. Epidemiology of febrile neutropenia in patients with hematological disease – a prospective multicentre survey in China. Chin J Hematol. 2016;37:177–182.
   Google Scholar
• Zhanel GG, Karlowsky JA, Rubinstein E, et al. Tigecycline: a novel glycylcycline antibiotic. Expert Rev Anti Infect Ther. 2006;4:9–25.
   PubMedGoogle Scholar
• Hu X, Sun A, Zheng J, et al. Efficacy observation of tigecycline in the treatment of 107 patients with infection due to granulocytopenia. Chin J Hematol. 2015;36:583–586.
   Google Scholar
• Schwab KS, Hahn-Ast C, Heinz WJ, et al. Tigecycline in febrile neutropenic patients with haematological malignancies: a retrospective case documentation in four university hospitals. Infection. 2014;42:97–104.
   PubMed Web of Science ®Google Scholar
• Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52:427–431.
   PubMed Web of Science ®Google Scholar
• Averbuch D, Orasch C, Cordonnier C, et al. European guidelines for empiric antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica. 2013;98:1826–1835.
   PubMed Web of Science ®Google Scholar
• Chinese Society of Hematology CMA. Chinese guidelines for the clinical application of antibacterial drugs for agranulocytosis with fever. Chin J Hematol. 2012;33:693–696.
   Google Scholar
• Gaya H, Klastersky J, Schimpff SC, et al. Protocol for an international prospective trial of initial therapy regimens in neutropenic patients with malignant disease. Eur J Cancer. 1975;11(l):1–4.
   Google Scholar
• Chemaly RF, Hanmod SS, Jiang Y, et al. Tigecycline use in cancer patients with serious infections: a report on 110 cases from a single institution. Medicine (Baltimore). 2009;88:211–220.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Nicolini L, Repetto E, et al. Tigecycline use in serious nosocomial infections: a drug use evaluation. BMC Infect Dis. 2010;10:287.
   PubMed Web of Science ®Google Scholar
• Bucaneve G, Micozzi A, Picardi M, et al. Results of a multicenter, controlled, randomized clinical trial evaluating the combination of piperacillin/tazobactam and tigecycline in high-risk hematologic patients with cancer with febrile neutropenia. J Clin Oncol. 2014;32:1463–1471.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Lourida P, Poulikakos P, et al. Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence. Antimicrob Agents Chemother. 2014;58:654–663.
   PubMed Web of Science ®Google Scholar
• Ni W, Han Y, Liu J, et al. Tigecycline treatment for carbapenem-resistant enterobacteriaceae infections: a systematic review and meta-analysis. Medicine (Baltimore). 2016;95:e3126.
   PubMed Web of Science ®Google Scholar
• Ramirez J, Dartois N, Gandjini H, et al. Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia. Antimicrob Agents Chemother. 2013;57:1756–1762.
   PubMed Web of Science ®Google Scholar
• Wu X, Zhu Y, Chen Q, et al. Tigecycline therapy for nosocomial pneumonia due to carbapenem-resistant gram-negative bacteria in critically Ill patients who received inappropriate initial antibiotic treatment: a retrospective case study. Biomed Res Int. 2016;2016:8395268.
   PubMed Web of Science ®Google Scholar
• De Pascale G, Montini L, Pennisi M, et al. High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. Crit Care. 2014;18:R90.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Peghin M, Pecori D. The management of multidrug-resistant Enterobacteriaceae. Curr Opin Infect Dis. 2016;29:583–594.
   PubMed Web of Science ®Google Scholar
• Andria N, Henig O, Kotler O, et al. Mortality burden related to infection with carbapenem-resistant Gram-negative bacteria among haematological cancer patients: a retrospective cohort study. J Antimicrob Chemother. 2015;70:3146–3153.
   PubMed Web of Science ®Google Scholar
• Tofas P, Skiada A, Angelopoulou M, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections in neutropenic patients with haematological malignancies or aplastic anaemia: analysis of 50 cases. Int J Antimicrob Agents. 2016;47:335–339.
   PubMed Web of Science ®Google Scholar
• Heizmann WR, Loschmann PA, Eckmann C, et al. Clinical efficacy of tigecycline used as monotherapy or in combination regimens for complicated infections with documented involvement of multiresistant bacteria. Infection. 2015;43:37–43.
   PubMed Web of Science ®Google Scholar
• Yahav D, Lador A, Paul M, et al. Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother. 2011;66:1963–1971.
   PubMed Web of Science ®Google Scholar
• Mouloudi E, Massa E, Piperidou M, et al. Tigecycline for treatment of carbapenem-resistant Klebsiella pneumoniae infections after liver transplantation in the intensive care unit: a 3-year study. Transplant Proc. 2014;46:3219–3221.
   PubMed Web of Science ®Google Scholar
• Gardiner D, Dukart G, Cooper A, et al. Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials. Clin Infect Dis. 2010;50:229–238.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Vardakas KZ, Tsiveriotis KP, et al. Effectiveness and safety of high-dose tigecycline-containing regimens for the treatment of severe bacterial infections. Int J Antimicrob Agents. 2014;44:1–7.
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Sanguinetti M, Montuori E, et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother. 2007;51:1987–1994.
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Trecarichi EM, De Rosa FG, et al. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother. 2015;70:2133–2143.
   PubMed Web of Science ®Google Scholar
• Bulik CC, Nicolau DP. Double-carbapenem therapy for carbapenemase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2011;55:3002–3004.
   PubMed Web of Science ®Google Scholar
• Ceccarelli G, Falcone M, Giordano A, et al. Successful ertapenem-doripenem combination treatment of bacteremic ventilator-associated pneumonia due to colistin-resistant KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2013;57:2900–2901.
   PubMed Web of Science ®Google Scholar
• Giamarellou H, Galani L, Baziaka F, et al. Effectiveness of a double-carbapenem regimen for infections in humans due to carbapenemase-producing pandrug-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother. 2013;57:2388–2390.
   PubMed Web of Science ®Google Scholar
• Oliva A, Mascellino MT, Cipolla A, et al. Therapeutic strategy for pandrug-resistant Klebsiella pneumoniae severe infections: short-course treatment with colistin increases the in vivo and in vitro activity of double carbapenem regimen. Int J Infect Dis. 2015;33:132–134.
   PubMed Web of Science ®Google Scholar
• Pournaras S, Vrioni G, Neou E, et al. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay. Int J Antimicrob Agents. 2011;37:244–247.
   PubMed Web of Science ®Google Scholar